There are 2789 resources available
278P - Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients
Presenter: Sergei Krasny
Session: ePoster Display
279P - Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
Presenter: Cristina Saura Manich
Session: ePoster Display
280P - Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
Presenter: Rupert Bartsch
Session: ePoster Display
281P - Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases
Presenter: Gaia Griguolo
Session: ePoster Display
282P - Methylthioadenosine phosphorylase (MTAP) genomic loss in ERBB2 amplified (amp) and mutated (mut) (ERBB2+) metastatic breast cancer (MBC)
Presenter: Abirami Sivapiragasam
Session: ePoster Display
283P - Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: ePoster Display
284P - Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study
Presenter: Seock-Ah Im
Session: ePoster Display
285P - Real-world outcomes associated with pyrotinib-based therapy for HER2-positive metastatic breast cancer
Presenter: Li Hao
Session: ePoster Display
312P - Survival of breast cancer patients with brain metastases treated with radiotherapy in Ontario, Canada: A population-based study
Presenter: Rania Chehade
Session: ePoster Display
313P - Use of PARPi among patients with advanced breast cancer
Presenter: Shaheenah Dawood
Session: ePoster Display